[Skip to Content]
[Skip to Content Landing]
Views 2,586
Citations 0
Clinical Trials Update
September 24, 2019

Adjuvant Therapy for HER2-Positive Breast Cancer

JAMA. 2019;322(12):1134. doi:10.1001/jama.2019.14757

Patients with small, human epidermal growth factor receptor 2 (HER2)–positive breast tumors treated with adjuvant paclitaxel and trastuzumab showed persistently high rates of disease-free survival (DFS) after a median follow-up of 6.5 years, reported a secondary analysis in Journal of Clinical Oncology.

In the initial trial, 406 patients with HER2-positive breast cancer with tumors 3 cm or smaller and negative nodes received weekly paclitaxel plus weekly trastuzumab for 12 weeks, followed by trastuzumab every 3 weeks for 9 months. (There wasn’t a control group because no standard of treatment existed at that time.) After a median follow-up of 4 years, patients had a 3-year DFS of 98.7% and few serious adverse events. In the recent secondary analysis, the 7-year DFS was 93.3% with only 4 (1.0%) distant recurrences.